Search results

96 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
NICE guidelines Remove NICE guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter

Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

Proposed [GID-HST10040] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]

Proposed [GID-HST10038] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Proposed [GID-HST10034] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Proposed [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Avalglucosidase alfa for treating Pompe disease [ID3737]

Proposed [GID-HST10030] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

Proposed [GID-HST10037] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Acne Vulgaris: Management: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 05 February 2021.

Type

NICE guideline

Status

In consultation
Shared decision making: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 09 February 2021.

Type

NICE guideline

Status

In consultation
Intrapartum care for healthy women and babies (update): draft scope consultation

We are listening to your views on this NICE guideline. Comments close 04 February 2021.

Type

NICE guideline

Status

In consultation
Advocacy services for adults with health and social care needs: draft scope consultation

We are listening to your views on this NICE guideline. Comments close 22 January 2021.

Type

NICE guideline

Status

In consultation
Clostridioides difficile infection: antimicrobial prescribing: draft guidance consultation

We are listening to your views on this antimicrobial prescribing guideline. Comments close 17 February 2021.

Type

NICE guideline

Status

In consultation
Chronic kidney disease: assessment and management (update): draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 19 March 2021.

Type

NICE guideline

Status

In consultation
Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 02 March 2021

Type

Antimicrobial prescribing guideline

Status

In development
Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 01 September 2021

Type

NICE guideline

Status

In development
OTL-200 for treating metachromatic leukodystrophy [ID1666]

In development [GID-HST10028] Expected publication date: 13 August 2021

Type

Highly specialised technologies guidance

Status

In development
Givosiran for treating acute hepatic porphyria [ID1549]

In development [GID-HST10035] Expected publication date: 04 August 2021

Type

Highly specialised technologies guidance

Status

In development
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: 24 February 2021

Type

Highly specialised technologies guidance

Status

In development
Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: 25 March 2021

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

In development [GID-HST10032] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-HST10033] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 06 April 2022

Type

NICE guideline

Status

In development
Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 10 February 2021

Type

NICE guideline

Status

In development
Looked-after children and young people

In development [GID-NG10121] Expected publication date: 27 September 2021

Type

NICE guideline

Status

In development
Stye: antimicrobial prescribing

In development [GID-NG10167] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Blepharitis: antimicrobial prescribing

In development [GID-NG10168] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Neonatal infection: antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 12 April 2021

Type

NICE guideline

Status

In development
Intrapartum care for healthy women and babies (update)

In development [GID-NG10174] Expected publication date: 22 March 2023

Type

NICE guideline

Status

In development
Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 09 December 2021

Type

NICE guideline

Status

In development
Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 10 May 2022

Type

NICE guideline

Status

In development
Weight Management

In development [GID-NG10182] Expected publication date: 22 June 2022

Type

NICE guideline

Status

In development
Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 25 August 2021

Type

NICE guideline

Status

In development
Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 22 June 2022

Type

NICE guideline

Status

In development
Barrett's oesophagus: ablative therapy

In development [GID-NG10165] Expected publication date: 23 January 2023

Type

NICE guideline

Status

In development
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 21 April 2021

Type

NICE guideline

Status

In development
Integrated health and social care for people experiencing homelessness

In development [GID-NG10170] Expected publication date: 16 March 2022

Type

NICE guideline

Status

In development
Depression in adults: treatment and management (update)

In development [GID-CGWAVE0725] Expected publication date: 12 May 2022

Type

NICE guideline

Status

In development
Self harm: assessment, management and preventing recurrence

In development [GID-NG10148] Expected publication date: 18 May 2022

Type

NICE guideline

Status

In development
Gout: diagnosis and management

In development [GID-NG10151] Expected publication date: 13 June 2022

Type

NICE guideline

Status

In development
Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management

In development [GID-NG10149] Expected publication date: 08 June 2022

Type

NICE guideline

Status

In development
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: TBC

Type

NICE guideline

Status

In development
Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 08 September 2021

Type

NICE guideline

Status

In development
Rehabilitation after traumatic injury

In development [GID-NG10105] Expected publication date: 23 November 2021

Type

NICE guideline

Status

In development